A Phase II, 6-week, Multicenter, Randomized, Double Blind (Patient and Investigator) or Masked, Placebo Controlled, Dose-finding Trial to Evaluate the Efficacy, Tolerability, and Safety of Different Doses of Oral BI 1569912 as Adjunctive Therapy in MD
Latest Information Update: 03 May 2025
At a glance
- Drugs BI 1569912 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
Most Recent Events
- 24 Mar 2025 Status changed from active, no longer recruiting to completed.
- 22 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 24 Dec 2024 Planned End Date changed from 18 Feb 2025 to 10 Mar 2025.